SOC2103
20 Apr 2022
SOC2103
NCT04851834
A Phase 1/2, Open-label, Dose-exploration and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NTX-301 Monotherapy in Advanced Solid Tumours, and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer, and in Combination With Temozolomide as Adjuvant (Maintenance) Therapy in High-grade Glioma (Optional Arm)
Xennials Therapeutics Australia
Cancer Type | All cancers; Gynaecological; Bladder |
---|---|
Trial Type | Treatment |
Phase | Phase I; Phase II |
Age Range | 18 years to 75 years |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2021-08-25 |
Anticipated End Date | 2023-11-01 |
Hospital | Southern Oncology Clinical Research Unit |
---|---|
Clinical Trial Coordinator | Meggan O'Riley |
Meggan.ORiley@socru.org.au | |
Phone | 0491 679 039 |
Principal Investigator | - |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs